Shryne Group

2 weeks ago | thebluntness.com | Harrison Wise |Shryne Group |Hemptown USA

New York’s legal cannabis program is once again under the microscope—and this time, the stakes are higher than ever. According to a recent report in The New York Times by Ashley Southall (April 7, 2025 article), multiple cannabis businesses across the state are being scrutinized for alleged violations, irregularities, and potential misconduct tied to licensing, operations, and state oversight.

3 weeks ago | thebluntness.com | Harrison Wise |Shryne Group |Hemptown USA |Taylor Engle

SXSW 2025, held from March 7 to 15 in Austin, Texas, prominently featured a Psychedelics Track, highlighting the expanding role of psychoactive substances in culture, medicine, and policy. The Psychedelics Track offered a diverse array of sessions aimed at broadening the understanding of psychoactive substances. Researchers, healthcare professionals, and investors gathered to discuss efforts to dissolve stigma and reshape perceptions of psychedelics.

Nov 22, 2024 | thebluntness.com | Harrison Wise |Shryne Group |Hemptown USA

For years, military veterans suffering from post-traumatic stress disorder (PTSD) have sought alternative treatments beyond traditional pharmaceuticals. Now, after years of regulatory hurdles and advocacy, the U.S. Food and Drug Administration (FDA) has approved a groundbreaking Phase 2 clinical trial to study the effects of smoked marijuana on veterans with moderate to severe PTSD.

Nov 7, 2024 | thebluntness.com | Harrison Wise |Shryne Group |Hemptown USA |Chris Faraone

In a world where public opinion often drives significant policy changes, few issues have seen a transformation as sweeping and impactful as marijuana legalization in the United States. Election night 2024 delivered a mix of victories and setbacks for cannabis reform advocates. While several initiatives succeeded at state and local levels, others faced formidable obstacles.

Nov 1, 2024 | thebluntness.com | Harrison Wise |Shryne Group |Hemptown USA |Chris Faraone

As New York’s cannabis industry enters its first major growth phase, a new report from Whitney Economics highlights the potential for the market to scale to $6 billion in annual sales within the next few years. Despite nearing $1 billion in annualized sales since adult-use legalization in 2021, only 15% of New York’s cannabis consumers currently buy from legal dispensaries.